Topics Discussed
- How biopharma business models are changing in China to meet evolving customer needs;
- China's latest policy initiatives meant to support biopharma innovation;
- The latest trends impacting patient access to mature and innovative drugs in China;
- Updated views on McKinsey's annual China Drug Innovation Index (CDII); and
- Key trends shaping the medtech environment in China.